Fondazione Italiana Linfomi - Ets

This study looks at whether adding lenalidomide to the standard drug rituximab (called R2) can help keep follicular lymphoma from coming back longer than rituximab alone. It involves 128 adults whose lymphoma returned after previous treatment and who cannot have a stem cell trans…

This study observes how patients with Waldenström's macroglobulinemia (a rare blood cancer) are treated with the drug zanubrutinib in Italy, both through a compassionate use program and after it was approved for sale. Researchers will track side effects and why some patients stop…

This study tests a combination of the targeted drug ibrutinib with standard chemotherapy (R-CHOP) in 75 adults under 65 with a specific, aggressive type of lymphoma called ABC-DLBCL. After initial treatment, those who respond well continue ibrutinib alone for 18 months to help ke…

This study compares a shorter chemotherapy regimen combined with immunotherapy to the standard full-length treatment for people with newly diagnosed, advanced follicular lymphoma that has a high tumor burden. About 605 participants will be randomly assigned to either the shortene…

This study tests adding the drug romidepsin to standard chemotherapy (CHOEP) in young adults (ages 18-65) with a rare type of lymphoma called peripheral T-cell lymphoma. The goal is to see if this combination is safe and effective before patients receive a stem cell transplant. A…

This study looks at stored tissue samples from 160 adults with mantle cell lymphoma whose cancer came back or didn't respond to initial chemotherapy and rituximab. Researchers want to find genetic and cellular clues that explain why the cancer becomes resistant. The goal is to be…

This study reviews the medical records of 241 adults who developed PTLD after an organ or stem cell transplant. The goal is to understand patient survival, identify common features of the disease, and see how different treatments are currently used. By learning from past cases, r…